Do analysts rate PLYX or CGC?

Polaryx Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 295.19%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Polaryx Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better valuation & earnings, PLYX or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A -$8.98M -$0.08 N/A Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A

Is PLYX or TTRX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Turn Therapeutics N/A -230.84% -53.19%

Which has preferable valuation and earnings, PLYX or RLMD?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A -$8.98M -$0.08 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is PLYX or RLMD more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Relmada Therapeutics N/A -47.52% -43.97%

Polaryx Therapeutics (PLYX) Competitors

$1.99 +0.05 (+2.78%)

As of 12:02 PM Eastern

Compare

PLYX vs. CGC, FENC, ENTA, TTRX, and RLMD

Should you buy Polaryx Therapeutics stock or one of its competitors? Polaryx Therapeutics's main competitors and comparable companies include Canopy Growth (CGC), Adherex Technologies (FENC), Enanta Pharmaceuticals (ENTA), Turn Therapeutics (TTRX), and Relmada Therapeutics (RLMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Polaryx Therapeutics compare to Canopy Growth?

Polaryx Therapeutics (NASDAQ:PLYX) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Polaryx Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 295.19%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Polaryx Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Polaryx Therapeutics has higher earnings, but lower revenue than Canopy Growth. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Canopy Growth	$251.01M	1.36	-$190.29M	-$0.45	N/A

Polaryx Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Polaryx Therapeutics' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Canopy Growth	-65.33%	-21.91%	-14.34%

In the previous week, Canopy Growth had 7 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 8 mentions for Canopy Growth and 1 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.79 beat Canopy Growth's score of 0.98 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Polaryx Therapeutics	Very Positive
Canopy Growth	Positive

3.3% of Canopy Growth shares are held by institutional investors. 45.8% of Polaryx Therapeutics shares are held by company insiders. Comparatively, 0.4% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Polaryx Therapeutics beats Canopy Growth on 10 of the 13 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

In the previous week, Adherex Technologies and Adherex Technologies both had 1 articles in the media. Adherex Technologies' average media sentiment score of 1.82 beat Polaryx Therapeutics' score of 1.79 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adherex Technologies	Very Positive
Polaryx Therapeutics	Very Positive

Adherex Technologies currently has a consensus price target of $17.00, indicating a potential upside of 66.99%. Polaryx Therapeutics has a consensus price target of $7.67, indicating a potential upside of 295.19%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has lower revenue, but higher earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	8.01	-$9.74M	-$0.13	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

55.5% of Adherex Technologies shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Polaryx Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Polaryx Therapeutics' return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Polaryx Therapeutics beats Adherex Technologies on 9 of the 13 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 1 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.79 beat Enanta Pharmaceuticals' score of 0.22 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Polaryx Therapeutics	Very Positive

Enanta Pharmaceuticals currently has a consensus target price of $19.00, indicating a potential upside of 64.93%. Polaryx Therapeutics has a consensus target price of $7.67, indicating a potential upside of 295.19%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Polaryx Therapeutics' return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.14	-$81.89M	-$2.41	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Summary

Polaryx Therapeutics beats Enanta Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Turn Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

In the previous week, Turn Therapeutics had 7 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 8 mentions for Turn Therapeutics and 1 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.79 beat Turn Therapeutics' score of 0.34 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Polaryx Therapeutics	Very Positive
Turn Therapeutics	Neutral

Polaryx Therapeutics' return on equity of 0.00% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Turn Therapeutics	N/A	-230.84%	-53.19%

Polaryx Therapeutics presently has a consensus price target of $7.67, suggesting a potential upside of 295.19%. Turn Therapeutics has a consensus price target of $9.00, suggesting a potential downside of 15.09%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Polaryx Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50

Turn Therapeutics is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Summary

Polaryx Therapeutics beats Turn Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Relmada Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Polaryx Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 295.19%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 257.14%. Given Polaryx Therapeutics' higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

In the previous week, Polaryx Therapeutics and Polaryx Therapeutics both had 1 articles in the media. Polaryx Therapeutics' average media sentiment score of 1.79 beat Relmada Therapeutics' score of 0.95 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Polaryx Therapeutics	Very Positive
Relmada Therapeutics	Positive

Polaryx Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Relmada Therapeutics	N/A	-47.52%	-43.97%

45.2% of Relmada Therapeutics shares are held by institutional investors. 45.8% of Polaryx Therapeutics shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Polaryx Therapeutics beats Relmada Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Polaryx Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLYX vs. The Competition

Export

Metric	Polaryx Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$99.20M	$12.43B	$7.28B	$13.01B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-24.88	807.81	275.44	25.42
Price / Sales	N/A	748.21	559.80	78.81
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	19.94	9.19	10.66	5.96
Net Income	-$8.98M	$2.84B	$3.50B	$380.62M
7 Day Performance	-4.59%	-3.85%	-3.65%	-3.75%
1 Month Performance	-1.29%	-7.95%	-8.06%	-6.62%
1 Year Performance	N/A	-5.71%	2.58%	-4.38%

Polaryx Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLYX Polaryx Therapeutics	2.6922 of 5 stars	$1.99 +2.8%	$7.67 +284.5%	N/A	$99.20M	N/A	N/A	11	Positive News
CGC Canopy Growth	1.1956 of 5 stars	$0.83 -2.3%	N/A	-44.3%	$380.47M	$251.01M	N/A	1,128
FENC Adherex Technologies	4.4808 of 5 stars	$10.71 +0.8%	$17.00 +58.7%	+20.6%	$373.52M	$44.64M	N/A	35	Positive News
ENTA Enanta Pharmaceuticals	2.1121 of 5 stars	$12.50 +3.3%	$19.00 +52.0%	+0.3%	$352.42M	$65.32M	N/A	120	Analyst Downgrade Gap Up
TTRX Turn Therapeutics	1.9174 of 5 stars	$12.00 +5.4%	$9.00 -25.0%	N/A	$339.29M	N/A	N/A	2	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLYX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. CGC, FENC, ENTA, TTRX, and RLMD

How does Polaryx Therapeutics compare to Canopy Growth?

Summary

How does Polaryx Therapeutics compare to Adherex Technologies?

Summary

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Turn Therapeutics?

Summary

How does Polaryx Therapeutics compare to Relmada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. CGC, FENC, ENTA, TTRX, and RLMD

How does Polaryx Therapeutics compare to Canopy Growth?

Do analysts rate PLYX or CGC?

Which has higher valuation & earnings, PLYX or CGC?

Is PLYX or CGC more profitable?

Does the media favor PLYX or CGC?

Do insiders and institutionals have more ownership in PLYX or CGC?

Summary

How does Polaryx Therapeutics compare to Adherex Technologies?

Does the media favor FENC or PLYX?

Do analysts prefer FENC or PLYX?

Which has preferable earnings & valuation, FENC or PLYX?

Do insiders and institutionals have more ownership in FENC or PLYX?

Is FENC or PLYX more profitable?

Summary

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Do institutionals & insiders have more ownership in ENTA or PLYX?

Does the media prefer ENTA or PLYX?

Do analysts rate ENTA or PLYX?

Is ENTA or PLYX more profitable?

Which has higher earnings & valuation, ENTA or PLYX?

Summary

How does Polaryx Therapeutics compare to Turn Therapeutics?

Does the media refer more to PLYX or TTRX?

Is PLYX or TTRX more profitable?

Do analysts rate PLYX or TTRX?

Which has better valuation & earnings, PLYX or TTRX?

Summary

How does Polaryx Therapeutics compare to Relmada Therapeutics?

Do analysts recommend PLYX or RLMD?

Which has preferable valuation and earnings, PLYX or RLMD?

Does the media refer more to PLYX or RLMD?

Is PLYX or RLMD more profitable?

Do insiders and institutionals hold more shares of PLYX or RLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools